Overview

Eligibility

Design Details

Arms & Interventions

Outcome Measures

Trial Sites

Source: NCT05223647

Terminated

TRIPLEX: Chemo-immunotherapy Plus Thoracic Radiotherapy in Extensive Stage Small-cell Lung Cancer

Interventional

Phase 3

Linköping University Hospital

Sponsor: Norwegian University of Science and Technology

Last Updated: June 6, 2025
Notice- Information is sourced from public registries and may not reflect real-time changes at the local site.

Studies have shown that combining chemotherapy and immune checkpoint inhibitors (ICI) prolongs survival compared with chemotherapy alone in extensive stage small-cell lung cancer (ES SCLC), but the survival benefit is modest. The main aim of this trial is to investigate whether there is a synergistic/additive effect of concurrent thoracic radiotherapy in ES SCLC patients receiving carboplatin/etoposide/durvalumab.

Show Detailed Description

Treatment Category

Procedure, Other Drugs

Required Mutations

None

Trial Started

January 11, 2022

Last Updated by Sponsor

June 6, 2025

Estimated Completion

January 1, 2026

Contact Study

Name:Bjørn H Grønberg, MD, PhD

Email:bjorn.h.gronberg@ntnu.no

Phone:47297878

Name:Trude C Frøseth, MSc

Email:triplex@stolav.no

Phone:N/A

Eligibility

Inclusion Criteria

1. Age > 18 years at time of study entry

2. ECOG performance status of 0 or 1

3. Body weight >30 kg

4. Adequate bone marrow, liver and kidney function

5. Life expectancy of at least 3 months

6. At least one measurable (RECIST 1.1), thoracic lesion that can be irradiated with 30 Gy/10 fractions

7. Histologically or cytologically confirmed SCLC

8. Stage III-IV disease (TNM v8)

9. FEV1 >1 L or >30 % of predicted value and DLCO >30 % of predicted value

10. Patients with brain metastases are eligible provided they are asymptomatic or treated and stable on steroids and/or anticonvulsants prior to the start of treatment

Exclusion Criteria

1. Previous chemo-, immuno- or radiotherapy for SCLC

2. Major surgical procedure last 28 days

3. History of allogenic organ transplantation, autoimmune disease, immunodeficiency, hepatitis or HIV

4. Uncontrolled intercurrent illness

5. Other active malignancy

6. Leptomeningeal carcinomatosis

7. Immunosuppressive medication

8. Pregnant or breastfeeding women

Do you think this trial is incorrectly appearing?

Design Details

AllocationRandomized

Intervention ModelParallel Assignment

MaskingNone (Open Label)

Number to Enroll302

Arms & Interventions

Arms

Interventions

Type: Experimental

Description: Four courses of carboplatin/etoposide/durvalumab every 3 weeks followed by durvalumab every 4 weeks until intolerable toxicity, progressive disease leading to a need for other treatment, or until the patient no longer wishes to continue treatment. Thoracic radiotherapy of 30 Gy/10 fractions between 2nd and 3rd carboplatin/etoposide/durvalumab course.

Interventions:

Thoracic radiotherapy
Chemo-immunotherapy

Outcome Measures

Primary Outcome Measures

Change in 1-year overall survival14 months after last patient entry

The Cox proportional hazards method will be used to compare survival between the treatment groups.

Secondary Outcome Measures

Change in 2-, 3-, 4- and 5-year survival rate2, 3, 4 and 5 years after last patient entry

The Cox proportional hazards method will be used to compare survival between the treatment groups.

Frequency and severity of adverse eventsThrough study completion, an average of 1 year after last patient entry

Adverse events will be compared between the treatment arms using the Pearson's Chi-square and Fisher's exact test.

Change in progression free survival (PFS)Through study completion, an average of 1 year after last patient entry

PFS will be estimated using the Kaplan-Meier method and compared using the log-rank test. A Cox-model adjusting for baseline characteristics will be used for multivariable analyses.

Change in overall response ratesThrough study completion, an average of 1 year after last patient entry

Response rates are compared using Pearson's Chi-square test.

Change in response rates in non-irradiated lesionsThrough study completion, an average of 1 year after last patient entry

Response rates are compared using Pearson's Chi-square test.

Local control rates in the thoraxThrough study completion, an average of 1 year after last patient entry

Local control rates are compared using Pearson's Chi-square test.

Health-related quality of life (HRQoL)Through study completion, an average of 1 year after last patient entry

All HRQoL scores will be transformed to a scale of 0-100 according to the EORTC QLQ scoring manual. Mean scores will be compared at each assessment timepoint, and a difference of 10 points is considered clinically relevant.

Change in cognitive function from baseline to end of treatmentThrough study completion, an average of 2 years after last patient entry

Cognitive function will be compared between patients who receive PCI and those who do not, using the MoCA-test. Scores will be compared using the Mann-Whitney test.

Frequency and timing of brain metastasesThrough study completion, an average of 2 years after last patient entry

Changes in brain metastases are compared using Pearson's Chi-square test.

Associations between outcomes of study treatment and biomarkers in tissue, blood and stoolThrough study completion, an average of 2 years after last patient entry

A detailed plan for analyses will be defined when sufficient material for translational research has been collected.

Bookmark trial

Share Trial

Download Trial

Do you think this trial is incorrectly appearing?

Report Trial

Download Trial

Trial Sites

This study has 20 trial sites

Linköping University Hospital

Linköping, SE

Name:Anders Vikström

Recruiting

Linköping, SE

Linköping University Hospital

Recruiting

Bergen, NO

Haukeland Universitetssykehus

Recruiting

Levanger, NO

Sykehuset Levanger

Recruiting

Tromsø, NO

University Hospital of North Norway, Pulmonology Department

Recruiting

Trondheim, NO

Cancer Clinic at St. Olavs Hospital

Recruiting

Göteborg, SE

Sahlgrenska Sjukehuset

Recruiting

Stockholm, SE

Karolinska University Hospital

Recruiting

Ålesund, NO

Ålesund Hospital

Recruiting

Rotterdam, NL

Erasmus MC

Recruiting

Stavanger, NO

Stavanger University Hospital

Recruiting

Drammen, NO

Drammen sykehus - Vestre Viken

Recruiting

Oslo, NO

Akershus Universitetssykehus AHUS

Recruiting

Oslo, NO

Oslo University Hospital Ullevål

Recruiting

Tallinn, EE

North Estonia Medical Centre

Recruiting

Haugesund, NO

Haugesund hospital

Recruiting

Gävle, SE

Gävle hospital

Recruiting

Gjøvik, NO

Innlandet hospital Gjøvik

Recruiting

Reykjavík, IS

Landspitali University Hospital

Recruiting

Bodø, NO

Nordlandssykehuset HF

Recruiting

Skåne, SE

Lund University Hospital

Loading Maps...